OphthalmologyNews.net

Ophthalmology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Uveitis"

A single-masked Phase I/II clinical study of the investigational drug Lucentis ( Ranibizumab ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degenera ...


A study by researchers at Johns Hopkins’ Wilmer Eye Institute, showed that immunosuppressive drug Mycophenolate Mofetil ( CellCept ), used to prevent rejection of transplanted hearts, kidneys and live ...


Taking oral antiviral medications following infection with the herpes simplex virus may be associated with a reduced risk of recurring eye-related manifestations of the disease.Herpes simplex virus ( ...


Corticosteroids are the mainstay of treatment for immune-mediated diseases, including non-infectious uveitis and ocular inflammation, because they are inexpensive, potent and rapidly effective. Howeve ...


All three commonly used TNF blockers ( Infliximab, Etanercept and Adalimumab ) were initially approved for the treatment of rheumatoid arthritis, and were subsequently approved for a number of other s ...


A new study published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus ( AAPOS ) suggests that the biologic agent Adalimumab ( Humira ) may be a viable treatment o ...


A study has assessed the safety and efficacy of Tocilizumab ( Actemra; RoActemra ) in patients with severe and refractory non-infectious uveitis. Eight consecutive unselected patients with severe a ...


The aim of a study was to assess the clinical response to Golimumab ( Simponi ) in patients with non-infectious uveitis from a single centre that had previously been treated with other anti-TNF-alpha ...


The clinical and demographic profile of uveitis-related ocular hypertension ( OHT ) was studied and risk factors predisposing to development of ocular hypertension in uveitis were evaluated. Two ...


Tumour necrosis factor ( TNF ) blockers have been demonstrated to be effective in the treatment of systemic and ocular inflammatory diseases. Researchers have conducted a prospective, multicentre, o ...


The aim of a study was to assess the efficacy of Adalimumab ( Humira ) in patients with active non-infectious uveitis in three different centres. In a retrospective study researchers have identifie ...


Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our un ...


Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibited promising activity in a proof-of-concept study when administered in intravenous ( IV ) doses to patients with active, chr ...